Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Effect of Exenatide and Dapagliflozin on Glucose Production in T2DM
NCT02981069Phase 4Completed
- Sponsor
- UT Health San Antonio
- Start
- Dec 2017
- Primary completion
- Jul 2022
- Modality
- Peptides
- Countries
- 1
01
Overview
A Phase 4 trial of exenatide in type 2 diabetes mellitus (T2DM), sponsored by UT Health San Antonio. Started Dec 2017; status: completed.
02
Drugs
exenatide
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT02981069.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02981069.